<DOC>
	<DOCNO>NCT00277225</DOCNO>
	<brief_summary>The purpose protocol determine single-dose pharmacokinetics immunogicity BMS-188667 administer 1 hour intravenous infusion extend pharmacokinetic sampling . Safety subject assess double blind fashion inclusion placebo control dose level .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics , Immunogenicity Safety Escalating Doses BMS-188667 Given Single Intravenous Infusion Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subjects require know diagnosis psoriasis vulgaris involve 549 % total body surface area ( BSA ) least six month prior randomization . Subjects clinically insignificant abnormal laboratory ECG test result otherwise healthy meet remain eligibility criterion . Evidence active bacterial viral infection time enrollment , include history clinical evidence infection Human Immunodeficiency virus ( HIV ) Hepatitis B Hepatitis C. Any underlie metabolic , hematologic , pulmonary , cardiac , renal hepatic , infectious , psychiatric gastrointestional condition , opinion investigator , place subject unacceptable risk participation study potentially immunosuppresive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>